Is the price fair?
What UTHR's price assumes
United Therapeutics Corporation trades at 18.4× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
18.4
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · cheaper than the typical name in its group
- Price / sales
- 8.83
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.4%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- +7.3%
Growth the price implies · The price pays for +7.3% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.
Details›
- Price / book2026-Q1
- 4.74
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Free cash flow, trailing twelve months
- $1.02B
- Market capitalisation
- $23.1B
- 3-year revenue growth
- +17%
- 3-year free cash flow growth
- +12%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $321.41 |
| Its own P/E history, median | $363.41 |
| Its own P/E history, upper quartile | $422.45 |
| 52-week range | $304.76 – $596.76 |
| Today | $498.10 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #9 of 29 by Smart Score